. 2020 Jun 29;12(7):1721. doi: 10.3390/cancers12071721

Table 1.

(A) Half-maximal inhibitory concentrations (IC50) of taccalonolides in HeLa cells. (B) Details of in vivo tumor xenograft studies in mice using taccalonolides AF and AJ. IC50 of (C) persin and its analogues, and (D) curcumin, maytansine, combretastatin, noscapine, and quercetin in various cancer cell lines.

(A)

Compound

IC₅₀ (μM)

Compound

IC₅₀ (μM)

Compound

IC₅₀ (μM)

Compound

IC₅₀ (μM)

Compound

IC₅₀

Compound

IC₅₀ (μM)

References:
[24,26,30,31,32]

Taccalonolide A

5.32 ± 0.23

Taccalonolide N

8.5 ± 0.40

Taccalonolide Z

0.12 ± 0.008

Taccalonolide AD

3.4 ± 0.2

Taccalonolide AO

>50

Taccalonolide AN

1.5 ± 0.1

Taccalonolide B

3.12 ± 0.18

Taccalonolide I

49.2 ± 2.8

Taccalonolide AA

0.032 ± 0.002

Taccalonolide AE

5.0 ± 0.2

Taccalonolide AK

>50

Paclitaxel

0.0012 ± 0.1

Taccalonolide E

39.5 ± 4.70

Taccalonolide R

13.0 ± 1.0

Taccalonolide AB

2.7 ± 0.1

Taccalonolide AF

0.023 ± 0.003

Taccalonolide AL

34.4 ± 7.5

Taccalonolide H2

0.73 ± 0.02

Taccalonolide T

0.34 ± 0.02

Taccalonolide AC

>50

Taccalonolide AJ

0.0042 ± 0.0003

Taccalonolide AM

2.0 ± 0.1

(B)

Compound

Xenograft Models

Method of Tumor Cell Administration

Treatment Strategy/Dose

References

Taccalonolide AF and AJ

MDA-MB-231 breast cancer

intraperitoneal

1. Taccalonolide AF: 2 mg/kg on Days 1, 4, 8
2. Taccalonolide AF: 2.5 mg/kg on Days 1 and 5
3. Taccalonolide AJ: 0.5 mg/kg on Days 1, 3, 5, and 8

[27]

Taccalonolide AF and AJ

SCC-4 oral cancer cells

subcutaneous

1. Taccalonolide AF: 80 μg on Days 0 and 3
2. Taccalonolide AJ: 40 μg on Days 0 and 3
3. Taccalonolide AJ: 80 μg on Days 0 and 3

[34]

(C)

Breast Cancer Cell Lines

Ovarian Cancer Cell Lines

Prostate Cancer Cell Lines

Leukemia Cell Lines

References:
[35,36,37]

Compound (μM)

MCF-7

T-47D

MDA-MB-468

MDA-MB-157

SK-BR3

Hs578T

MDA-MB-231

MCF-10A

OVCAR-3

IGROV-1

1A9

A2780

PC-3

LNCaP

HL-60

Persin

15.1 ± 1.3

30.3 ± 2.3

25.0 ± 2.8

12.8 ± 1.2

19.7 ± 1.3

32.1 ± 2.3

>39

27.9 ± 4.5

15.6 ± 3.6

13.7 ± 0.6

8.1 ± 1.1

30.0 ± 3.0

22.0 ± 1.8

1.9 ± 0.1

17.1 ± 1.7

20.7 ± 3.2

>39

4.1 ± 0.4

8.1 ± 1.4

>39

0.6 ± 0.03

>32

18.9 ± 1.3

13.7 ± 0.9

4.0 ± 0.1

27.7 ± 5.5

19.4 ± 2.2

2.6 ± 0.4

>27

21.2 ± 1.8

7.5 ± 0.2

23.8 ± 2.2

34.1 ± 5.3

5.8 ± 0.1

29.0 ± 4.2

47.6 ± 3.5

28.4 ± 0.5

>21

>24

20.1 ± 3.6

>65

124 ± 20

22.8 ± 1.0

(D)

Breast Cancer Cell Lines

Lung Cancer Cell Lines

Squamous Carcinoma Cell Lines

Lymphoma Cell Lines

Ovarian Cancer Cell Line

Cervical Cancer Cell Line

Leukemia Cell Line

Prostate Cancer Cell Line

References

Compound

MCF7

MDA-MB-231

BT-474

SK-BR3

MDA-MB-435

A594

H1299

H292

NCI-H358M

Tu212

Tu686

BJAB

OVCAR-8

HeLa

HL60

LNCap

PC3M

Curcumin (μM)

11.2

6.03

11.6

5.5

6.4

25.0

[38,39,40,41,42]

Maytansine (pM)

420

270

[43,44,45]

Combretastatin A4 (nM)

2.8

5.3

3.8

0.37

0.9

2.1

4.7

[46,47]

Noscapine (μM)

[48]

Quercetin (μM)

[49]